<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492582</url>
  </required_header>
  <id_info>
    <org_study_id>UAB-F141204009/UAB-X141204010</org_study_id>
    <secondary_id>NCI-2011-03654</secondary_id>
    <secondary_id>1R01CA166559</secondary_id>
    <secondary_id>Merck-IISP#40083</secondary_id>
    <secondary_id>COH-11034</secondary_id>
    <nct_id>NCT01492582</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors</brief_title>
  <official_title>Quadrivalent Human Papillomavirus (qHPV) Vaccine in Cancer Survivors: Cross Sectional Survey and Phase II Open-Label Vaccine Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer
      survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine
      initiation among young cancer survivors, and (2) determining the immune response to and
      safety/tolerability of the quadrivalent and nonavalent HPV vaccine in young cancer survivors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Using a cross-sectional survey approach, estimate the prevalence of HPV vaccine
      non-initiation: a) Examine sociodemographic, behavioral, and medical determinants of HPV
      vaccine non-initiation.

      II. Using a single-arm, phase II, open-label, prospective longitudinal trial design, to
      evaluate the 3-dose HPV quadrivalent (HPV4) and nonavalent (HPV9) vaccine series and measure
      the following endpoints: a) Determine immunogenicity following the third and final vaccine
      dose; b) Identify clinical/host factors influencing immunogenicity; c) Determine the
      safety/tolerability of the HPV vaccine in cancer survivors.

      III. Evaluate the persistence of antibody response at 2 years post vaccine initiation and
      identify clinical/host factors influencing response persistence.

      OUTLINE:

      AIM 1 (SURVEY): Patients (ages 18-26 years) or their parents (for patients ages 9-17 years)
      complete a survey regarding the patient's HPV vaccination status, knowledge of HPV-related
      disease, and factors important in making decisions regarding vaccination.

      AIM 2 (VACCINE EVALUATION): Patients not previously immunized against HPV receive
      quadrivalent human papillomavirus recombinant vaccine (HPV-6, -11, -16, -18, for patients
      enrolled on or before 3/1/16) or the nonavalent human papillomavirus recombinant vaccine
      (HPV-6, -11, -16, -18, -31, -33, -45, -52, -58, for patients enrolled after 3/1/16)
      intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Actual">February 8, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of HPV Vaccine Initiation in Cancer Survivors (Aim 1 [Survey])</measure>
    <time_frame>At baseline</time_frame>
    <description>The prevalence of HPV vaccine initiation in cancer survivors ages 9 to 26 years</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of the HPV Vaccine in Cancer Survivors (Anti-HPV 16 and 18 Geometric Mean Titers) (Aim 2 [Vaccine Evaluation])</measure>
    <time_frame>1 month following vaccination dose #3</time_frame>
    <description>To demonstrate the non-inferiority of the antibody responses to the HPV vaccine in cancer survivors ages 9 to 26 years when compared to antibody responses of age- and sex-matched historical healthy population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Tolerability of the HPV Vaccine in Cancer Survivors (Aim 2 [Vaccine Evaluation])</measure>
    <time_frame>Dose 1 through Month 7</time_frame>
    <description>To demonstrate comparable safety/tolerability of the HPV vaccine in cancer survivors ages 9 to 26 years when compared to age- and sex-matched general population.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1499</enrollment>
  <condition>Cancer Survivor</condition>
  <condition>Prevention of Human Papillomavirus Infection</condition>
  <arm_group>
    <arm_group_label>Prevention (vaccine therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Prevention (vaccine therapy)</arm_group_label>
    <other_name>Gardasil</other_name>
    <other_name>Gardasil 9</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Prevention (vaccine therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>survey administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Prevention (vaccine therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Prevention (vaccine therapy)</arm_group_label>
    <other_name>chart review</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AIM 1 (SURVEY) (AIM 1 is closed to enrollment)

          -  Cancer survivor

          -  Between 12 and 60 months after completion of cancer therapy (chemotherapy, radiation,
             hematopoietic cell transplant [HCT])

          -  Scheduled for a return clinic visit at one of the participating institutions

          -  English or Spanish-speaking

          -  Willing to provide informed consent/assent for study participation

          -  AIM 2 (VACCINE EVALUATION)

          -  Meets all inclusion criteria outlined in Aim 1

          -  Survey response indicated no prior history of HPV vaccination OR patient has no prior
             history of HPV vaccination by self - or parent/caregiver-report

          -  English or Spanish-speaking

          -  Medical clearance from treating clinician for study participation

          -  Agrees to return to participating institution for 3 HPV vaccine injections

          -  Willing to provide informed consent/assent for study participation

        Exclusion Criteria:

          -  AIM 2 (VACCINE EVALUATION)

          -  Allergy to any component of the HPV vaccine including yeast and aluminum

          -  Thrombocytopenia (platelet count &lt; 50K) or coagulation disorder that would
             contraindicate intramuscular injection

          -  Transfusion of blood products or intravenous immune globulin within 3 months of study
             entry

          -  Female, and a) currently pregnant or lactating, or b) of childbearing potential and
             unwilling to avoid pregnancy during the vaccine phase of study (beginning at Day 1 and
             continuing until at least 4 weeks after all 3 vaccine doses have been administered)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Landier, PhD, CRNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School Of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <results_first_submitted>February 6, 2020</results_first_submitted>
  <results_first_submitted_qc>April 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2020</results_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Wendy Landier</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT01492582/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT01492582/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prevention (Vaccine Therapy)</title>
          <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.
laboratory biomarker analysis: Correlative studies
survey administration: Ancillary studies
medical chart review: Ancillary studies</description>
        </group>
        <group group_id="P2">
          <title>Survey Arm</title>
          <description>Patients (ages 18-26 years) or their parents (for patients ages 9-17 years) complete a survey regarding the patient's HPV vaccination status, knowledge of HPV-related disease, and factors important in making decisions regarding vaccination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="453">Consented to the vaccine arm (265 quadrivalent vaccine; 188 nonavalent vaccine)</participants>
                <participants group_id="P2" count="1046">Consented to the survey arm of the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received First Quadrivalent Vaccine Dose</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="0">Does not apply</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received First Nonavalent Vaccine Dose</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="384">Received 3 vaccine doses and completed Month 7 blood draw (224 quadrivalent; 160 nonavalent)</participants>
                <participants group_id="P2" count="982">Returned evaluable survey</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who consented to the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Prevention (Vaccine Therapy)</title>
          <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Survey</title>
          <description>Patients (ages 18-26 years) or their parents (for patients ages 9-17 years) complete a survey regarding the patient's HPV vaccination status, knowledge of HPV-related disease, and factors important in making decisions regarding vaccination.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="453"/>
            <count group_id="B2" value="1046"/>
            <count group_id="B3" value="1499"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>9-15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="508"/>
                    <measurement group_id="B3" value="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16-26 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="538"/>
                    <measurement group_id="B3" value="742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="473"/>
                    <measurement group_id="B3" value="668"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="573"/>
                    <measurement group_id="B3" value="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="400"/>
                    <measurement group_id="B2" value="900"/>
                    <measurement group_id="B3" value="1300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="338"/>
                    <measurement group_id="B2" value="796"/>
                    <measurement group_id="B3" value="1134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                    <measurement group_id="B2" value="1046"/>
                    <measurement group_id="B3" value="1499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of HPV Vaccine Initiation in Cancer Survivors (Aim 1 [Survey])</title>
        <description>The prevalence of HPV vaccine initiation in cancer survivors ages 9 to 26 years</description>
        <time_frame>At baseline</time_frame>
        <population>Participants who returned an evaluable survey</population>
        <group_list>
          <group group_id="O1">
            <title>Survey Participants</title>
            <description>Participants who consented to the survey aim of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of HPV Vaccine Initiation in Cancer Survivors (Aim 1 [Survey])</title>
          <description>The prevalence of HPV vaccine initiation in cancer survivors ages 9 to 26 years</description>
          <population>Participants who returned an evaluable survey</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="982"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity of the HPV Vaccine in Cancer Survivors (Anti-HPV 16 and 18 Geometric Mean Titers) (Aim 2 [Vaccine Evaluation])</title>
        <description>To demonstrate the non-inferiority of the antibody responses to the HPV vaccine in cancer survivors ages 9 to 26 years when compared to antibody responses of age- and sex-matched historical healthy population.</description>
        <time_frame>1 month following vaccination dose #3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Anti-HPV 16, Male, Age 9-15 Years</title>
            <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Anti-HPV 16, Female, Age 9-15 Years</title>
            <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Quadrivalent Anti-HPV 16, Male, Age 16-26 Years</title>
            <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Quadrivalent Anti-HPV 16, Female, Age 16-26 Years</title>
            <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Nonavalent Anti-HPV 16, Male, Age 9-15 Years</title>
            <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Nonavalent Anti-HPV 16, Female, Age 9-15 Years</title>
            <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Nonavalent Anti-HPV 16, Male, Age 16-26 Years</title>
            <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Nonavalent Anti-HPV 16, Female, Age 16-26 Years</title>
            <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Quadrivalent Anti-HPV 18, Male, Age 9-15 Years</title>
            <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Quadrivalent Anti-HPV 18, Female, Age 9-15 Years</title>
            <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Quadrivalent Anti-HPV 18, Male, Age 16-26 Years</title>
            <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Quadrivalent Anti-HPV 18, Female, Age 16-26 Years</title>
            <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Nonavalent Anti-HPV 18, Male, Age 9-15 Years</title>
            <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O14">
            <title>Nonavalent Anti-HPV 18, Female, Age 9-15 Years</title>
            <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O15">
            <title>Nonavalent Anti-HPV 18, Male, Age 16-26 Years</title>
            <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O16">
            <title>Nonavalent Anti-HPV 18, Female, Age 16-26 Years</title>
            <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of the HPV Vaccine in Cancer Survivors (Anti-HPV 16 and 18 Geometric Mean Titers) (Aim 2 [Vaccine Evaluation])</title>
          <description>To demonstrate the non-inferiority of the antibody responses to the HPV vaccine in cancer survivors ages 9 to 26 years when compared to antibody responses of age- and sex-matched historical healthy population.</description>
          <units>mMu/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="53"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="66"/>
                <count group_id="O10" value="54"/>
                <count group_id="O11" value="68"/>
                <count group_id="O12" value="30"/>
                <count group_id="O13" value="50"/>
                <count group_id="O14" value="41"/>
                <count group_id="O15" value="32"/>
                <count group_id="O16" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16134.57" spread="14722.06"/>
                    <measurement group_id="O2" value="15209.73" spread="15638.30"/>
                    <measurement group_id="O3" value="8740.02" spread="9625.61"/>
                    <measurement group_id="O4" value="6107.32" spread="6609.07"/>
                    <measurement group_id="O5" value="16419.64" spread="14756.37"/>
                    <measurement group_id="O6" value="11763.60" spread="8082.14"/>
                    <measurement group_id="O7" value="10770.38" spread="11166.73"/>
                    <measurement group_id="O8" value="11522.87" spread="10443.38"/>
                    <measurement group_id="O9" value="3472.21" spread="3769.68"/>
                    <measurement group_id="O10" value="2638.33" spread="2695.70"/>
                    <measurement group_id="O11" value="1920.01" spread="2553.81"/>
                    <measurement group_id="O12" value="1009.90" spread="990.48"/>
                    <measurement group_id="O13" value="5599.80" spread="4522.19"/>
                    <measurement group_id="O14" value="3457.20" spread="2510.32"/>
                    <measurement group_id="O15" value="3013.39" spread="3194.84"/>
                    <measurement group_id="O16" value="3483.29" spread="6869.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
QUADRIVALENT
Male and female, all age groups:
Merck Pub 9883616 (Gardasil Package Insert, April 2011, pp 24-26)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.74</param_value>
            <ci_n_sides>1-Sided</ci_n_sides>
            <estimate_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
QUADRIVALENT
Male and female, all age groups:
Merck Pub 9883616 (Gardasil Package Insert, April 2011, pp 24-26)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.76</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
QUADRIVALENT
Male and female, all age groups:
Merck Pub 9883616 (Gardasil Package Insert, April 2011, pp 24-26)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>2.15</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
QUADRIVALENT
Male and female, all age groups:
Merck Pub 9883616 (Gardasil Package Insert, April 2011, pp 24-26)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.00</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
QUADRIVALENT
Male and female, all age groups:
Merck Pub 9883616 (Gardasil Package Insert, April 2011, pp 24-26)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.52</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
QUADRIVALENT
Male and female, all age groups:
Merck Pub 9883616 (Gardasil Package Insert, April 2011, pp 24-26)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.48</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
QUADRIVALENT
Male and female, all age groups:
Merck Pub 9883616 (Gardasil Package Insert, April 2011, pp 24-26)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>2.48</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
QUADRIVALENT
Male and female, all age groups:
Merck Pub 9883616 (Gardasil Package Insert, April 2011, pp 24-26)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.00</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
NONAVALENT
Girls 9-15, Boys 9-15, Women 16-26:
Petersen LK, Restrepo J, Moreira ED, Jr., et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Res. 2017;3:105-115;</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI GMT ratio</param_type>
            <param_value>1.23</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
NONAVALENT
Girls 9-15, Boys 9-15, Women 16-26:
Petersen LK, Restrepo J, Moreira ED, Jr., et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Res. 2017;3:105-115;</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.12</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
NONAVALENT
Men 16-26:
Castellsague X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892-6901. (HM data).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.46</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
NONAVALENT
Girls 9-15, Boys 9-15, Women 16-26:
Petersen LK, Restrepo J, Moreira ED, Jr., et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Res. 2017;3:105-115;</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.61</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
NONAVALENT
Girls 9-15, Boys 9-15, Women 16-26:
Petersen LK, Restrepo J, Moreira ED, Jr., et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Res. 2017;3:105-115;</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.39</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
NONAVALENT
Girls 9-15, Boys 9-15, Women 16-26:
Petersen LK, Restrepo J, Moreira ED, Jr., et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Res. 2017;3:105-115;</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.10</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
NONAVALENT
Men 16-26:
Castellsague X, Giuliano AR, Goldstone S, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892-6901. (HM data).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>1.65</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O16</group_id>
            </group_id_list>
            <groups_desc>Historical Healthy Population Reference:
NONAVALENT
Girls 9-15, Boys 9-15, Women 16-26:
Petersen LK, Restrepo J, Moreira ED, Jr., et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Res. 2017;3:105-115;</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the one-sided 99.688% confidence interval (CI) of the geometric mean titer (GMT) ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>lower bound one-sided CI of GMT ratio</param_type>
            <param_value>-0.44</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <other_analysis_desc>GMT ratio = GMT (cancer survivor) / GMT (historical healthy population)</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety/Tolerability of the HPV Vaccine in Cancer Survivors (Aim 2 [Vaccine Evaluation])</title>
        <description>To demonstrate comparable safety/tolerability of the HPV vaccine in cancer survivors ages 9 to 26 years when compared to age- and sex-matched general population.</description>
        <time_frame>Dose 1 through Month 7</time_frame>
        <population>Note: 254 participants received the first dose of the quadrivalent vaccine. However, one participant never returned to clinic or returned phone calls after receiving the first vaccine. No follow-up information is available for this participant so only 253 participants are reported in this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Vaccine Therapy)- Quadrivalent</title>
            <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Nonavalent Vaccine</title>
            <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety/Tolerability of the HPV Vaccine in Cancer Survivors (Aim 2 [Vaccine Evaluation])</title>
          <description>To demonstrate comparable safety/tolerability of the HPV vaccine in cancer survivors ages 9 to 26 years when compared to age- and sex-matched general population.</description>
          <population>Note: 254 participants received the first dose of the quadrivalent vaccine. However, one participant never returned to clinic or returned phone calls after receiving the first vaccine. No follow-up information is available for this participant so only 253 participants are reported in this group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site - Pain, any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site - Swelling, any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site - Erythema, any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic - Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic - Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic - Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic - Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic - Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Injection site - Pain, any; Injection site - Swelling, any; Injection site - Erythema, any; Systemic - Nausea Historical Healthy Population: Reported from Gardasil Package Insert 04/2015, Tables 1, 2, 5, and 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Systemic - Fever Historical Healthy Population: Reported from Gardasil Package Insert 04/2015, Tables 1, 2, 5, and 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Systemic - Dizziness Historical Healthy Population: Reported from Gardasil Package Insert 04/2015, Tables 1, 2, 5, and 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection site - Pain, any; Injection site - Swelling, any; Injection site - Erythema, any; Systemic - Nausea; Systemic - Fatigue Historical Healthy Population - As reported by Moreira et. al, 2016, Pediatrics, Table 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Systemic - Headache Historical Healthy Population - As reported by Moreira et. al, 2016, Pediatrics, Table 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Systemic - Fever Historical Healthy Population - As reported by Moreira et. al, 2016, Pediatrics, Table 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Systemic - Dizziness Historical Healthy Population - As reported by Moreira et. al, 2016, Pediatrics, Table 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Other (Not Including Serious) Adverse Events: Nonavalent: 7 days after each vaccine dose Quadrivalent: 14 days after each vaccine dose Serious Adverse Events were reported up to Month 7 (no SAEs occurred within 7-14 days of each vaccine dose).</time_frame>
      <desc>No adverse events are reported for the survey arm participants as adverse events were not monitored/assessed for participants in this arm.
Note: 254 participants received the first dose of the quadrivalent vaccine. However, one participant never returned to clinic or returned phone calls after receiving the first vaccine. No follow-up information is available for this participant so only 253 participants are reported in this group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Prevention (Vaccine Therapy)- Quadrivalent</title>
          <description>Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Prevention (Vaccine Therapy)- Nonavalent Vaccine</title>
          <description>Patients receive nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for endocrine disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for fluid-electrolyte disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for musculoskeletal issue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Relapse of primary cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Subsequent malignant neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for neurologic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for psychiatric disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain or Tenderness, any</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling, any</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema, any</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Fever (≥100.0⁰F)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wendy Landier, Deputy Director, Institute for Cancer Outcomes and Survivorship</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>(205) 638-2120</phone>
      <email>wlandier@peds.uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

